Breaking News

Financial Report: Johnson & Johnson

July 15, 2014

Revenues up 9% in the quarter driven by new products

Johnson & Johnson
2Q Revenues: $19.5 billion (+9%)

2Q Earnings: $4.3 billion (+13%)

YTD Revenues: $37.6 billion (+6%)

YTD Earnings: $9.1 billion (+24%)

Comments: Pharmaceutical sales were $8.5 billion, up 21%, with domestic sales up 37% and international sales up 7%. Growth was primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA for type 2 diabetes; and IMBRUVICA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Sales were negatively impacted by loss of exclusivity for ACIPHEX for gastrointestinal disorders, and CONCERTA, an ADHD treatment.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks